<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905467/" ref="ordinalpos=1594&amp;ncbi_uid=2985165&amp;link_uid=PMC2905467" image-link="/pmc/articles/PMC2905467/figure/F2/" class="imagepopup">Figure 2.  From: ?-Adrenoceptor Inverse Agonists in Asthma. </a></div><br /><div class="p4l_captionBody">Alternative signaling by β2-ARs. Activation of β2-AR leads to both β-arrestin-dependent and G protein-dependent signaling. Acute β2-AR activation attenuates the asthma phenotype via the G protein-dependent pathway in airway smooth muscle cells. The asthma inflammation phenotype is significantly diminished when β2-AR or β-arrestin-2 is absent or when a β2-AR inverse agonist is chronically administered. The dotted lines represent a proposed pathway underlying the asthma phenotype that requires activation of a β2-AR-mediated β-arrestin-2-dependent signaling pathway. (β2-AR, beta-2-adrenergic receptor; βarr2, β-arrestin-2; KO, knock-out; MAPK, mitogen-activatged protein kinase; AHR, airway hyperresponsiveness; ASM, airway smooth muscle).</div></div>